Navigation Links
Mortality Data Presented for Patients Treated with Efient®/Effient® (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery
Date:11/16/2010

rgo urgent CABG surgery. The risk of bleeding is increased in patients receiving prasugrel who undergo CABG. If possible, prasugrel should be discontinued at least 7 days prior to CABG.(4)

Study Methodology

TRITON-TIMI 38 was a Phase III, randomized, double-blind, head-to-head clinical trial comparing the effects of prasugrel versus clopidogrel in patients with ACS who were managed with percutaneous coronary intervention (PCI), a procedure to open blockages in heart arteries, including the use of coronary stenting. The study enrolled 13,608 patients at 707 trial sites in 30 countries.

The primary endpoint of the study was the combined incidence of cardiovascular death, non-fatal heart attack or non-fatal stroke during at least 12 months following PCI. Patients were randomly assigned to one of two treatment groups and given a loading dose of either prasugrel 60 mg or the FDA-approved loading dose of clopidogrel 300 mg, followed by a daily maintenance dose of either prasugrel 10 mg or clopidogrel 75 mg. All patients also received a daily dose of aspirin (75 mg to 325 mg).(4,5)

This retrospective analysis included newly collected data on 346 patients who underwent isolated CABG following withdrawal of study drug, either prasugrel (n=173) or clopidogrel n=173), during the TRITON-TIMI 38 study.(2) Possible baseline imbalances between arms were adjusted using European System for Cardiac Operative Risk Evaluation (EuroSCORE) and Society of Thoracic Surgeons (STS) scoring, two widely accepted and standardized methods of calculating cardiac operative mortality risk.(2) Bleeding was measured by chest tube blood loss, a standard methodused by surgeons.(2) Despite the adjustment for predicted risk of mortality at the time of CABG, this non-randomized comparison between prasugrel  and clopidogrel may be subject to potential residual biases.(2)

About TRITON-TIMI 38 Results

In the overall TRITON-TIMI 38 trial, treatment
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
2. Robotic Prostatectomy Expert Dr. David Samadi Talks About Big Strides in the Fight Against Prostate Cancer - Mortality Rate Declines 45%
3. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
4. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
5. Increased Mortality Associated With Nocturia
6. Unemployment, Health Care Spending Affect Mortality
7. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
8. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
9. Study Shows Use of AdvanDxs PNA FISH(TM) Test was Associated with an 82% Reduction in Intensive Care Unit Mortality Rates from Staphylococcus aureus Bloodstream Infections
10. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
11. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/23/2014)... A pilot study by Massachusetts General Hospital (MGH) investigators ... unusual treatment for a serious medical problem use ... diarrhea caused by the Clostridium difficile ( ... published online in the journal Clinical Infectious Diseases ... fecal material from donors unrelated to patients was as ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... A Michigan State University researcher is looking to give ... workout, and her latest research shows that a cyber ... the Games for Health Journal , is the ... still a better motivator during exercise, a software-generated partner ... that something that isn,t real can still motivate people ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... the gastro-intestinal tract has long been considered to be ... Sahlgrenska Academy have used refined microscopic techniques that indicate ... of the gastro-intestinal tract is only as large as ... The digestive tract, which passes from the mouth through ... length of about 5 meters in a normal adult, ...
Breaking Medicine News(10 mins):Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2
... Record Profitability and 12th Consecutive Year of Record ... ... $164 ... ST. LOUIS, Feb. 15 KV Pharmaceutical Company,(NYSE: KVa/KVb), a fully integrated ...
... One day doctors may recommend using high efficiency ... smoking cessation, and exercise to improve cardiovascular health, ... study, they found that using HEPA filters for ... of cardiovascular health in healthy, non-smoking elderly individuals. ...
... single prostate specific antigen (PSA) test at age 50 or ... 25 years later, (regardless of clinical significance) have now found ... prostate cancer. , The findings, published in the online ... men would benefit from intensive screening. , More men die ...
... Penn Bancshares Inc. (NASD:,NPBC) will replace Bradley Pharmaceuticals Inc. ... the close of trading on Thursday, February 21, 2008. ... on or about that date,pending final approvals., Standard ... relevant,updates on its website: http://www.standardandpoors.com ., National ...
... killer, but the recent findings of four Texas A&M University ... the dreaded disease. , Diabetics not only have high ... levels because they have trouble metabolizing glucose and fatty acids. ... acid aspects of diabetes separately because there was nothing linking ...
... Following the,company,s announcement of record unaudited revenues ... nutritional product manufacturer subsidiary InterACTIVE,Nutrition International, Inc., ... Board: NNTN) http://www.naturalnutritioninc.com ,announced today the ... common stock.,Each shareholder will receive one additional ...
Cached Medicine News:Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 2Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 3Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 4Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 5Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 6Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 7Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 8Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 9Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 10Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 11Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 12Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 13Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 14Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 15Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 16Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 17Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 18Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 19Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 20Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 21Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 22Health News:KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE 23Health News:Using HEPA filters may improve cardiovascular health 2Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:Standard & Poor's Announces Change to U.S. Index 2Health News:Research findings may lead to new ways to study and fight diabetes 2Health News:Research findings may lead to new ways to study and fight diabetes 3Health News:Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year 2
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
... (ECP) is a surgical approach to glaucoma ... laser application. The ciliary body (which produces ... from the anterior or posterior segment, through ... tissues are easily and accurately identified utilizing ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek® ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... a surgical approach to glaucoma management that ... The ciliary body (which produces aqueous humour) ... anterior or posterior segment, through the endoscope ... easily and accurately identified utilizing endoscopy. This ...
Medicine Products: